Table 3 Published studies from MENA region analyzing BRCA mutations in early onset breast cancer
Study | No. patients | Family history | BRCA Analyzed regions | Screening method | BRCA mutation rate, Notes |
|---|---|---|---|---|---|
Morocco | |||||
 Tazzite et al. [16] | 4 | SBC | BRCA1/2 | Direct sequencing | 25% |
 Laraqui et al. [17] | 102 | SBC | BRCA1 | Direct sequencing | 1% |
 Tazzite et al. [18] | 28 | Unknown FHa | BRCA1 (Ex2, 11a, and 11b) | Direct sequencing | 12.2% b |
 Jouali et al. [19] | 15 | FBC | BRCA1/2 | NGS, direct sequencing | 26.7% |
 The present study | 33 | Unselected BC | BRCA1/2 | NGS | BC (≤40 y), unselected: 15.1% FBC (≤40 y): 16.7% SBC (≤40 y): 15.4% BC (≤35 y): 23.5% BC (36–40 y): 6.2% |
Algeria | |||||
 Uhrhammer et al. [20] | 51 | SBC | BRCA1 | Direct sequencing, MLPA | 9.8% |
 Cherbal et al. [21] | 52 | FBC | BRCA1/2 | HRM, Direct sequencing, MLPA | 13.5% |
 Henouda et al. [13] | 40 | Unselected BC | BRCA1/2 | Direct sequencing, MLPA | 20% |
Tunisia | |||||
 Mahfoudh et al. [22] | 7 | FBC | BRCA1 | Direct sequencing | 42.9% |
 Riahi et al. [23] | 4 | FBC | BRCA1/2 | Direct sequencing | 0% |
Egypt | |||||
 Ibrahim et al. [24] | 39 15 | FBC SBC | BRCA1/2 | SSCP (BRCA1: Ex2, 8, 13, 22; BRCA2: Ex9) Heteroduplex, direct sequencing | FBC (≤45 y): 89.7% |
Lebanon | |||||
 El Saghir et al. [12] | 148 102 | Unselected BC FBC | BRCA/2 | Direct sequencing, MLPA | BC (≤40 y), unselected: 6% FBC (≤40 y): 10.8% SBC (≤40 y): 1.4% FBC (41–50 y): 5.3% FBC (> 50 y): 3.7% |
Iran | |||||
 Yassaee et al. [25] | 83 | Unselected BC | BRCA1 (Ex2,3,5,11, 13 and 20) BRCA2 (Ex9,10,11, 17,18 and 23) | PTT, SSCP | 6.02% FBC: 28.6% SBC: 1.5% |
 Pietschmann et al. [26] | 41 | FBC | BRCA1/2 | Direct sequencing, Semi-quantitative multiplex PCR (BRCA1) | 9.8% LR: 0% |
 Keshavarzi et al. [27] | 49 36 | SBC FBC | BRCA1/2 (Except BRCA1:Ex1 and 4; and BRCA2: Ex1) | Direct sequencing | Global mutation rate: 11.8% |
 Yassaee et al. [28] | 254 | FBC | BRCA1/2 | SSCP, PPT, MLPA, and direct sequencing | Global mutation rate: 18% MS: 39.1% Indels: 15.2% LR: 6% |
 Ebrahimi et al. [15] | NA | Unselected BC | BRCA1/2 | NGS | 0% |
Jordan | |||||
 Abdel-Razeq et al. [14] | 51 | Unselected BC | BRCA1/2 | Comprehensive BRAC Analysis® and BRAC Analysis® Rearrangement Test (BART) | Global mutation rate: 26% FBC: 32.5% SBC: 0% TN: 50% |
Syria | |||||
 Khalil et al. [29] | 32 18 | FBC SBC | BRCA1 (Ex2) BRCA2 (Ex11) | Direct sequencing | 15.6% 0% No association between age (≤40 y) and exon 11 mutations |
Palestine | |||||
 Hamameh et al. [30] | 79 186 | FBC SBC | BRCA1/2 | NGS | 16.5% 2.7% |
Saudi Arabia | |||||
 Alhuqail et al. [31] | 108 | Unselected BC | BRCA1/2 | NGS | 8.3% No correlation between age and mutation status |
 Abulkhair et al. [32] | 66 | FBC | BRCA1/2 | NGS MLPA | BRCA1: 9.3% No association between age and mutation status |